An investigational therapeutic vaccine getting developed to treat herpes simplex virus-2.

Antigenics announces positive results of AG-707 genital herpes vaccine Antigenics announced excellent results with AG-707, an investigational therapeutic vaccine getting developed to treat herpes simplex virus-2 , the virus that causes genital herpes, in infected sufferers. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells. Recent data suggest both these arms of immunity are needed for successful treatment of genital herpes tadalafil 5 mg .D., study investigator and professor of Medicine, Laboratory Global and Medicine Health Medication, University of Washington.

cialis en espaƱa

Superoxide also degrades one of the enzymes that functions as a precursor to nitric oxide, leading to even lower levels of the chemical substance and reduced dilation of blood vessels. This, in turn, increases the risk of cardiovascular disease. Superoxide is required to keep up cellular function, but as the physical body ages, mitochondria begin to produce it in higher amounts. Simultaneously, levels of antioxidants in the body often decrease with age, which leads to higher circulating degrees of superoxide even.

Random entries

Other entries from category "drugs":